Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dialypro is an oral dietary supplement developed by H.A.C. Pharma, specifically classified as a "dietary food for special medical purposes" (FSMP) for the dietary management of patients undergoing dialysis. It is a protein-energy powder enriched with high-nutritional-value proteins and calories to compensate for insufficient oral intake and protein loss common in renal failure. The formulation is specifically designed to be low in electrolytes (sodium, potassium), phosphorus, and vitamin A to adhere to the strict dietary restrictions required for dialysis patients. It contains essential micronutrients including vitamins C and E (antioxidants), trace elements (iron, zinc, selenium), calcium, and L-carnitine. Dialypro is flavorless and soluble, intended for use under medical supervision as a supplement to a standard diet rather than an exclusive source of nutrition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dialypro.